Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 14/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25791870 | 1.00 | USP1 (0.43) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL31496744 | 0.91 | USP1 (0.38) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL29295998 | 0.88 | USP1 (0.44) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL29864073 | 0.88 | USP1 (0.37) | USP1MMP13PTGS2 | |
| SCHEMBL30320395 | 0.87 | USP1 (0.43) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL22143119 | 0.87 | USP1 (0.45) | USP1PTGS2 | |
| SCHEMBL22143054 | 0.87 | USP1 (0.43) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL18865694 | 0.87 | USP1 (0.43) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL30320408 | 0.86 | USP1 (0.44) | USP1MMP13PTGS2HDAC1HDAC6 | |
| SCHEMBL25791872 | 0.86 | USP1 (0.44) | USP1MMP13PTGS2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083237-A1 | SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2024-04-25 | — | — | WO | disclosed |
| EP-4291559-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Tango Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022174184-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |